Fortified Voriconazole
Voriconazole 1% · compounded ophthalmic solution
Antifungal
Approved uses
Invasive aspergillosis; candidemia in non-neutropenic patients and other deep tissue Candida infections; esophageal candidiasis; serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. in patients intolerant of, or refractory to, other therapy (adults and pediatric patients 2 years of age and older; intravenous, non-ocular)
Adults: 6 mg/kg IV every 12 hours for the first 24 hours, then a maintenance dose of 4 mg/kg IV every 12 hours (3 mg/kg to 4 mg/kg for candidemia and other deep tissue Candida infections) or 200 mg orally every 12 hours; esophageal candidiasis: 200 mg orally every 12 hours, IV dosing not evaluated; adults who weigh less than 40 kg should receive half of the oral maintenance dose. Pediatric patients 2 to less than 12 years of age and 12 to 14 years of age with body weight less than 50 kg: 9 mg/kg IV every 12 hours for the first 24 hours, then 8 mg/kg IV every 12 hours or 9 mg/kg orally every 12 hours (maximum dose of 350 mg every 12 hours); esophageal candidiasis: 4 mg/kg IV every 12 hours or 9 mg/kg orally every 12 hours (maximum dose of 350 mg every 12 hours), loading dose not evaluated. Pediatric patients 12 to 14 years of age weighing 50 kg or more and those 15 years of age and above: adult dosing.
OFF-LABELNot in the FDA label for this product
Filamentous fungal keratitis; inferior to natamycin as monotherapy, most of all for Fusarium (MUTT I)
1% (10 mg/mL) topically, 1 drop every hour while awake for 1 week, then every 2 hours while awake until 3 weeks from the start of treatment
RCT · n=323 · natamycin better
This regimen is the voriconazole arm of MUTT I, a phase 3 double-masked multicenter randomized trial of 323 smear-positive filamentous ulcers, and that trial found natamycin 5% superior: odds of corneal perforation or therapeutic penetrating keratoplasty were 0.42 with natamycin (95% CI 0.22 to 0.80, P = .009), with most of the difference from Fusarium cases while non-Fusarium cases fared similarly. The authors' own conclusion was that voriconazole should not be used as monotherapy in filamentous keratitis. A Cochrane review reached the same direction: reduced perforation or keratoplasty with natamycin (RR 0.61, 95% CI 0.40 to 0.94, 434 participants, high quality evidence), while its visual acuity estimate crossed no effect (mean difference -0.12 logMAR, 95% CI -0.31 to 0.06, low quality evidence).
Severe fungal keratitis, combined with topical natamycin
1% (10 mg/mL) topically alongside natamycin 5%, each 1 drop every hour while awake
Cohort · n=51 · nonrandomized
Prospective cohort of 51 fungal keratitis patients on empiric therapy: 88.9% of ulcers healed on natamycin plus voriconazole versus 39.1% on voriconazole alone (p = 0.018) and 52.6% on natamycin alone (p = 0.098, not significant). Interventions such as keratoplasty, anterior chamber wash, or a treatment change differed across arms (47.4% natamycin, 60.9% voriconazole, 11.1% combination, p = 0.034). The combination is not faster: median time to epithelialization was 65 days for the combination and 60 days for voriconazole alone versus 22 days for natamycin alone (log-rank p < 0.001). Arms were small (9, 23, and 19 patients), single-center, and not randomized. Application frequency comes from MUTT I, not from this cohort.
Recalcitrant deep fungal keratitis, intrastromal injection
50 mcg/0.1 mL intrastromal, given in cycles with amphotericin B 2.5 mcg/0.1 mL while topical antifungal therapy continues
Uncontrolled series · n=20
Uncontrolled case series of 20 consecutive culture-positive ulcers that had not responded to topical antifungals: best corrected acuity was worse than 20/400 in all 20 at presentation and improved to better than 20/400 in 11, while 7 required surgery. There is no control arm, so the effect cannot be separated from natural course or from the continued topical therapy. A Cochrane review found the single randomized comparison of topical 1% against intrastromal 50 mcg/0.1 mL (both on topical natamycin 5%) inconclusive because only one small trial was available. Listed here mainly because 50 mcg/0.1 mL equals 0.5 mg/mL and is easily confused with a drop concentration.
Contraindications
- Known hypersensitivity to voriconazole or its excipients
- Coadministration with pimozide, quinidine or ivabradine (QT prolongation and rare torsade de pointes)
- Coadministration with sirolimus
- Coadministration with rifampin, carbamazepine, long-acting barbiturates, or St John's Wort
- Coadministration of standard doses of voriconazole with efavirenz doses of 400 mg every 24 hours or higher
- Coadministration with high-dose ritonavir (400 mg every 12 hours)
- Coadministration with rifabutin
- Coadministration with ergot alkaloids (ergotamine and dihydroergotamine)
- Coadministration with naloxegol
- Coadministration with tolvaptan
- Coadministration with venetoclax at initiation and during the ramp-up phase in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
- Coadministration with lurasidone
Ophthalmic solution, compounded, no fixed ophthalmic package size, source single-dose vial 200 mg lyophilized powder, yields 20 mL of 10 mg/mL (1%) after reconstitution
Azole antifungal; its primary mode of action is inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14 alpha-methyl sterols correlates with the loss of ergosterol in the fungal cell wall and may be responsible for the antifungal activity. Shown to be active against most isolates of Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger, Aspergillus terreus, Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, Candida tropicalis, Fusarium spp. including Fusarium solani, and Scedosporium apiospermum, both in vitro and in clinical infections, although Fusarium isolates from corneal ulcers are the least susceptible filamentous genus.
Warnings & Precautions
- For Intravenous Infusion Only: The source vial is labeled for intravenous infusion only, so the topical ocular use on this card is outside the label. The linked label covers intravenous use only, so every ocular application is off-label.
- Single-dose unpreserved sterile lyophile: Once reconstituted, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user and should not be longer than 24 hours at 2°C to 8°C. Any unused solution should be discarded.
- Hepatic Toxicity: Serious hepatic reactions, including clinical hepatitis, cholestasis and fulminant hepatic failure with fatalities, occurred uncommonly, mainly in patients with serious underlying medical conditions. Measure serum transaminase levels and bilirubin at the start of therapy and at least weekly for the first month, then monthly if no clinically significant changes are noted. Discontinue if liver function tests become markedly elevated compared to baseline, unless benefit/risk justifies continued use.
- Arrhythmias and QT Prolongation: Rare cases of arrhythmias (including torsade de pointes), cardiac arrests and sudden deaths have been reported, usually in seriously ill patients with multiple confounding risk factors. Use with caution in potentially proarrhythmic conditions. Correct potassium, magnesium and calcium before starting and during therapy.
- Infusion Related Reactions: During intravenous infusion in healthy subjects, anaphylactoid-type reactions, including flushing, fever, sweating, tachycardia, chest tightness, dyspnea, faintness, nausea, pruritus and rash, have occurred uncommonly, starting immediately. Consider stopping the infusion if these reactions occur.
- Visual Disturbances: The effect of voriconazole on visual function is not known if treatment continues beyond 28 days. Post-marketing reports describe prolonged visual adverse reactions, including optic neuritis and papilledema. If treatment continues beyond 28 days, monitor visual function, including visual acuity, visual field, and color perception.
- Severe Cutaneous Adverse Reactions: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS), which can be life-threatening or fatal, have been reported. Discontinue voriconazole if a severe cutaneous adverse reaction develops.
- Photosensitivity: Patients, including pediatric patients, should avoid direct sunlight and use protective clothing and high-SPF sunscreen. Squamous cell carcinoma of the skin and melanoma have been reported during long-term therapy in patients with photosensitivity skin reactions. Refer phototoxic reactions to a dermatologist and consider discontinuation; discontinue for lesions consistent with premalignant skin lesions, squamous cell carcinoma or melanoma. Phototoxicity is more frequent in pediatric patients.
- Renal Toxicity: Acute renal failure has been observed in patients treated with voriconazole. Monitor for abnormal renal function, including serum creatinine.
- Adrenal Dysfunction: Reversible azole-induced adrenal insufficiency has been reported, including with voriconazole. Adrenal insufficiency has been reported with or without concomitant corticosteroids, and Cushing's syndrome with concomitant corticosteroids. Monitor patients on voriconazole and corticosteroids (via all routes of administration) for adrenal dysfunction during and after treatment, and instruct them to seek immediate medical care for signs and symptoms of Cushing's syndrome or adrenal insufficiency.
- Embryo-Fetal Toxicity: Voriconazole can cause fetal harm when administered to a pregnant woman. Inform pregnant patients of the potential hazard to the fetus, and advise females of reproductive potential to use effective contraception during treatment.
- Laboratory Tests: Correct electrolyte disturbances such as hypokalemia, hypomagnesemia and hypocalcemia before and during therapy, and monitor renal function (particularly serum creatinine) and hepatic function (particularly liver function tests and bilirubin).
- Pancreatitis: Pancreatitis has been observed during voriconazole treatment. Monitor patients with risk factors for acute pancreatitis, such as recent chemotherapy or hematopoietic stem cell transplantation (HSCT).
- Skeletal Adverse Reactions: Fluorosis and periostitis have been reported during long-term therapy. Discontinue voriconazole if skeletal pain and radiologic findings compatible with fluorosis or periostitis develop.
- Clinically Significant Drug Interactions: Voriconazole is metabolized by CYP2C19, CYP2C9, and CYP3A4, so inhibitors or inducers of these isoenzymes may increase or decrease voriconazole plasma concentrations. Voriconazole is a strong inhibitor of CYP3A4 and also inhibits CYP2C19 and CYP2C9, so it may increase the plasma concentrations of substances metabolized by these CYP450 isoenzymes. Review the patient's concomitant medications.
- Monotherapy failure in filamentous keratitis: In MUTT I, a randomized trial of 323 enrolled patients comparing voriconazole (1%) with natamycin (5%), natamycin-treated cases were less likely to have perforation or require therapeutic penetrating keratoplasty (odds ratio=0.42; 95% CI, 0.22 to 0.80). The authors wrote that voriconazole should not be used as monotherapy in filamentous keratitis.
Common Side Effects
- Topical ocular: Topical drops can cause ocular burning and irritation.
- Systemic, adults: With systemic dosing, the most common adult adverse reactions were visual disturbances (18.7%), fever (5.7%), nausea (5.4%), rash (5.3%), vomiting (4.4%), chills (3.7%), headache (3%), liver function test increased (2.7%), tachycardia (2.4%), and hallucinations (2.4%).
- Systemic, vision: Approximately 21% of patients experienced abnormal vision, color vision change and/or photophobia. In healthy subjects, 28 days of treatment decreased ERG waveform amplitude and the visual field and altered color perception, and all returned to normal 14 days after the end of dosing.
- Systemic, liver: Transaminase increases above 3 times the upper limit of normal (not necessarily an adverse reaction) occurred in 17.7% of adults.
- Systemic, pediatric: In pediatric patients, the most common included visual disturbances (26%), pyrexia (25%), vomiting (20%), epistaxis (16%), nausea (13%), and rash (13%).
- Topical voriconazole, retrospective case series: Among nine patients with fungal keratitis refractory to standard antifungal therapy, two discontinued topical voriconazole after one day and four weeks, respectively, because of ocular burning.
Pregnancy: Can cause fetal harm; no human data. Rat pups exposed during organogenesis showed hydroureter and hydronephrosis at and above 10 mg/kg (0.3 times the recommended human dose by body surface area) and cleft palate at 60 mg/kg (about 2 times), and rabbits dosed at 100 mg/kg (6 times) had embryomortality, reduced fetal weight, and skeletal variations. Rats exposed from implantation to weaning had increased gestational length and dystocia. If used during pregnancy, inform the patient of the potential hazard to the fetus. Advise females of reproductive potential to use effective contraception during treatment.
Lactation: No data on presence in human milk, on the breastfed infant, or on milk production.
Systemic use is established at 2 years and older and not recommended below age 2; no ophthalmic data.